GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Sino Biopharmaceutical Ltd (HKSE:01177) » Definitions » 5-Year Yield-on-Cost %

Sino Biopharmaceutical (HKSE:01177) 5-Year Yield-on-Cost % : 4.10 (As of Mar. 03, 2025)


View and export this data going back to 2003. Start your Free Trial

What is Sino Biopharmaceutical 5-Year Yield-on-Cost %?

Sino Biopharmaceutical's yield on cost for the quarter that ended in Jun. 2024 was 4.10.


The historical rank and industry rank for Sino Biopharmaceutical's 5-Year Yield-on-Cost % or its related term are showing as below:

HKSE:01177' s 5-Year Yield-on-Cost % Range Over the Past 10 Years
Min: 0.81   Med: 1.67   Max: 7.99
Current: 4.1


During the past 13 years, Sino Biopharmaceutical's highest Yield on Cost was 7.99. The lowest was 0.81. And the median was 1.67.


HKSE:01177's 5-Year Yield-on-Cost % is ranked better than
79.87% of 149 companies
in the Biotechnology industry
Industry Median: 1.69 vs HKSE:01177: 4.10

Competitive Comparison of Sino Biopharmaceutical's 5-Year Yield-on-Cost %

For the Biotechnology subindustry, Sino Biopharmaceutical's 5-Year Yield-on-Cost %, along with its competitors' market caps and 5-Year Yield-on-Cost % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Sino Biopharmaceutical's 5-Year Yield-on-Cost % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Sino Biopharmaceutical's 5-Year Yield-on-Cost % distribution charts can be found below:

* The bar in red indicates where Sino Biopharmaceutical's 5-Year Yield-on-Cost % falls into.



Sino Biopharmaceutical 5-Year Yield-on-Cost % Calculation

Dividend Yield % and dividend growth of a stock is an important factor for income investors. But if company A raises its dividend constantly faster than company B, company A's future dividend yield might be much higher than Company B's even if their yields are the same now and their stock prices do not change.

Yield on Cost assumes that you buy and the stock today, and hold it for 5 years. If the company raises it dividends at the same rate as it did over the past 5 years, the dividends investors receive annually in 5 years relative to the stock price today.

Therefore, Yield-on-Cost of Sino Biopharmaceutical is calculated as

Yield-on-Cost=Dividend Yield %*(1+Dividend Growth Rate)^5

Sino Biopharmaceutical  (HKSE:01177) 5-Year Yield-on-Cost % Explanation

Of course the risk here is that the company may not raise its dividends as it did before. The key is to select the companies that can consistently raise its dividends. Usually companies with long history of raising dividends tend to do so.


Sino Biopharmaceutical 5-Year Yield-on-Cost % Related Terms

Thank you for viewing the detailed overview of Sino Biopharmaceutical's 5-Year Yield-on-Cost % provided by GuruFocus.com. Please click on the following links to see related term pages.


Sino Biopharmaceutical Business Description

Traded in Other Exchanges
Address
1 Harbour Road, Unit 09, 41st Floor, Office Tower, Room 4109, Convention Plaza, Wanchai, Hong Kong, HKG
Listed on the Hong Kong Stock Exchange in 2000, Sino Biopharmaceutical is one of the largest Chinese drugmakers. It started with generic drug manufacturing. Since 2018, Sino Biopharm has been actively pivoting into an innovative drugmaker after the Chinese government launched its volume-based procurement policy for the healthcare industry. As of 2023, 37.8% of the firm's total revenue comes from five innovative drugs and five biosimilar drugs. Sino Biopharm's biggest revenue segment is oncology medicines, accounting for 33.6% of total revenue, followed by hepatitis, surgery/analgesia, respiratory, and cardio-cerebral vascular therapeutic areas.
Executives
Tse Ping 2101 Beneficial owner
Tse Eric S Y 2101 Beneficial owner
Cheng Cheung Ling 2101 Beneficial owner
True Merit Global Limited 2101 Beneficial owner
Tse Theresa Y Y 2101 Beneficial owner
Thousand Eagles Limited 2101 Beneficial owner
France Investment (china 1) Group Limited 2101 Beneficial owner
Remarkable Industries Limited 2101 Beneficial owner
Validated Profits Limited 2101 Beneficial owner

Sino Biopharmaceutical Headlines

No Headlines